SC
EW icon

Stance Capital’s Edwards Lifesciences EW Stock Holding History

Stance Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.05K Buy
+100
New +$8.38K ﹤0.01% 283
2025
Q4 		– Sell
-45,994
Closed -$3.58M – 187
2025
Q3 		$3.58M Buy
45,994
+36,272
+373% +$2.83M 1.31% 18
2025
Q2 		$760K Buy
+9,722
New +$725K 0.29% 140
2025
Q1 		– Sell
-23,148
Closed -$1.71M – 128
2024
Q4 		$1.71M Buy
+23,148
New +$1.62M 1.06% 34

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Stance Capital's EW Position: Q2 2026 in Review

Stance Capital opened a new position in Edwards Lifesciences (EW) in Q2 2026: 100 shares worth $9.05K. The stake represents ﹤0.01% of the portfolio and ranks #283 among its holdings. This is a return to the name: Stance Capital previously reported a position in EW as recently as Q3 2025.

Stance Capital first reported a position in EW in Q4 2024 and has held it in 4 quarters since. The position peaked at $3.58M in Q3 2025. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Stance Capital held 100 shares of Edwards Lifesciences worth $9.05K as of Q2 2026.
  • Edwards Lifesciences was a new Stance Capital position in Q2 2026.
  • Edwards Lifesciences made up ﹤0.01% of Stance Capital's portfolio in Q2 2026, its #283 holding.
  • Stance Capital first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 4 quarters since.
  • Stance Capital's Edwards Lifesciences position peaked at $3.58M in Q3 2025.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Stance Capital's 13F filing for Q2 2026, filed 14 Aug 2026.